Pfizer Inc.’s Ian Read was the highest-paid chief executive officer at a large pharmaceutical company last year, as U.S. top managers remained on average much better paid than their European counterparts.
Pfizer Inc. plans to keep its $3.2 billion-a-year consumer health business because the unit will be critical to selling prescription drugs that become over-the- counter products, Chief Executive Officer Ian Read said.
Pfizer Inc., the world’s largest drugmaker, put in place the last piece of its plan to refocus the company on developing new drugs, announcing it would start the separation of its animal-health business this month.
Pfizer Inc. Chief Executive Officer Ian Read received a 44 percent raise in total compensation last year to $25 million in his new role as head of the world’s largest drugmaker, according to a regulatory filing.
Pfizer Inc.’s industry-leading profit margins and disposal of non-drug businesses still haven’t closed the valuation gap with rival drugmakers. No wonder its chief executive officer is contemplating a full breakup.
Pfizer Inc. Chief Executive Officer Ian Read said he is reviewing the possible sale or spinoff of four divisions with $18.3 billion in annual revenue, led by the company’s third-biggest unit, established products.